{"symbol":"PFE","fiscalQuarter":"Q4-2021","reportDate":"2022-02-08","reportTime":"BMO","status":"reported","company":{"name":"Pfizer Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/PFE/earnings/Q4-2021","postBrief":{"headline":"Pfizer Beats on EPS, Stock Down 2.84%","keyNumbers":[{"metric":"EPS","actual":"$1.08","expected":"N/A","surprise":"+27.06%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key therapeutic areas.","They noted ongoing challenges in supply chain but remain focused on innovation."],"summary":"Overall, management expressed confidence in their pipeline and future prospects. However, they acknowledged external challenges that could impact growth."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Pfizer's earnings report showed a strong EPS beat, which indicates better-than-expected profitability. However, the stock fell by 2.84%, likely due to the absence of revenue figures and guidance, leaving investors uncertain about future performance. The cautious tone from management regarding external challenges may have also contributed to the stock's decline.","metaDescription":"Pfizer Inc (PFE) Q4 2021 earnings: EPS beat by 27.06%, revenue not disclosed. Stock down 2.84%. Full breakdown."}}